PTC Therapeutics (PTCT) came out with a quarterly loss of $1.83 per share versus the Zacks Consensus Estimate of a loss of $1.59. This compares to loss of $1.80 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.90 per share when it actually produced a loss of $1.08, delivering a surprise of -20%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
PTC Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $117.94 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 22.59%. This compares to year-ago revenues of $68.26 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.